Accessibility Menu
Pluri Stock Quote

Pluri (NASDAQ: PSTI)

$4.51
(0.7%)
+0.03
Price as of October 14, 2025, 2:32 p.m. ET

KEY DATA POINTS

Current Price
$4.09
Daily Change
(0.7%) +$0.03
Day's Range
$4.01 - $4.09
Previous Close
$4.09
Open
$4.01
Beta
0.85
Volume
5,757
Average Volume
9,438
Market Cap
33.4M
Market Cap / Employee
$4.09M
52wk Range
$3.33 - $7.13
Revenue
-
Gross Margin
0.25%
Dividend Yield
N/A
EPS
-$3.51
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Pluri Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PSTI-13.89%-94.73%-44.49%-100%
S&P+15.06%+95.03%+14.29%+665%

Pluri Company Info

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.40M314.6%
Gross Profit$0.10M209.7%
Gross Margin24.12%-8.2%
Market Cap$38.77M24.5%
Market Cap / Employee$0.31M0.0%
Employees12719.8%
Net Income-$7.77M-32.5%
EBITDA-$6.51M-9.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$6.32M-10.2%
Accounts Receivable$0.32M31.1%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$6.10M-79.0%
Short Term Debt$27.95M4899.6%

Ratios

Q2 2025YOY Change
Return On Assets-57.75%-11.5%
Return On Invested Capital-64.37%18.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$5.94M-37.3%
Operating Free Cash Flow-$5.22M-20.9%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-6.31-4.46-2.98-8.60-89.87%
Price to Sales55.2335.0127.3029.25-69.50%
Price to Tangible Book Value-6.31-4.46-2.98-8.60-89.87%
Enterprise Value to EBITDA-8.40-7.48-7.07-8.9248.19%
Return on Equity-173.6%-231.1%-310.6%-1205.6%-
Total Debt$30.88M$29.30M$31.19M$34.05M14.99%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.